# EDGAR Filing Document

**Accession Number:** 0001551152
**File Stem:** 0001104659-26-059484
**Filing Date:** 2026-5
**Character Count:** 5976
**Document Hash:** a4eb1330cb3df98e0d81c9d4464f2639
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-059484.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0001104659-26-059484

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260508

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AbbVie Inc.
- **CENTRAL INDEX KEY:** 0001551152
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 320375147
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35565
- **FILM NUMBER:** 26969675

**BUSINESS ADDRESS:**
- **STREET 1:** 1 NORTH WAUKEGAN ROAD
- **CITY:** NORTH CHICAGO
- **STATE:** IL
- **ZIP:** 60064
- **BUSINESS PHONE:** (847) 932-7900

**MAIL ADDRESS:**
- **STREET 1:** 1 NORTH WAUKEGAN ROAD
- **CITY:** NORTH CHICAGO
- **STATE:** IL
- **ZIP:** 60064

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 8, 2026

**ABBVIE INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35565** | **32-0375147** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

**1 North Waukegan Road**

**North Chicago, Illinois 60064-6400**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(847) 932-7900**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | **Name of each exchange on which registered** |
| &nbsp;&nbsp;Common Stock, $0.01 Par Value | &nbsp;&nbsp;ABBV | New York Stock Exchange |
|  |  | NYSE Texas |
| &nbsp;&nbsp;0.750% Senior Notes due 2027 | &nbsp;&nbsp;ABBV27 | New York Stock Exchange |
| &nbsp;&nbsp;2.125% Senior Notes due 2028 | &nbsp;&nbsp;ABBV28 | New York Stock Exchange |
| &nbsp;&nbsp;2.625% Senior Notes due 2028 | &nbsp;&nbsp;ABBV28B | New York Stock Exchange |
| &nbsp;&nbsp;2.125% Senior Notes due 2029 | &nbsp;&nbsp;ABBV29 | New York Stock Exchange |
| &nbsp;&nbsp;1.250% Senior Notes due 2031 | &nbsp;&nbsp;ABBV31 | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026. The following is a summary of the matters voted on at that meeting.

(1) The stockholders elected AbbVie's Class II directors with terms expiring in 2029, as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name | For | Against | Abstain | Broker Non-Votes |
| Jennifer L. Davis | 1216558754 | 89839329 | 2680369 | 239399581 |
| Melody B. Meyer | 1284771578 | 22470074 | 1836800 | 239399581 |
| Robert A. Michael | 1221224370 | 85865852 | 1988230 | 239399581 |
| Frederick H. Waddell | 1225237825 | 81747033 | 2093594 | 239399581 |

---

(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2026, as follows:

<u>For</u> <u>Against</u> <u>Abstain</u> <br> 1,522,575,012 23,766,564 2,136,457

(3) The stockholders approved, on an advisory basis, the compensation of AbbVie's named executive officers, as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 1228615745 | 69336359 | 11126348 | 239399581 |

---

(4) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 1290990023 | 14896119 | 3192310 | 239399581 |

---

(5) The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 515626009 | 787253970 | 6198473 | 239399581 |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **ABBVIE INC.** |
| Date: | May 12, 2026 | By: | /s/ Perry C. Siatis |
|  |  |  | Perry C. Siatis |
|  |  |  | Executive Vice President, General Counsel and Secretary |

---